Germantown, MDNCT07611396Now EnrollingIRB Ready

Alzheimer s Disease Clinical Trial in Germantown, MD

Access cutting-edge alzheimer s disease treatment through this clinical trial at a research site in Germantown. Study-provided care at no cost to qualified participants.

Sponsored by Crownlands

Quick Self-Assessment

See if you qualify for this Germantown location

Preparing your pre-screening questions…

Expert Care in Germantown

Access alzheimer s disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related alzheimer s disease treatment provided free

Apply for This Germantown Location

Check if you qualify for this alzheimer s disease clinical trial in Germantown, MD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Germantown

    Convenient for MD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Germantown site if eligible
  4. 4Begin participation

About This Alzheimer s Disease Study in Germantown

The CROWN-I Study is an observational study to learn about molecular features of Alzheimer's disease (AD) and mild cognitive impairment (MCI). The primary objective is to identify the molecular and genetic modules that differentiate patient subtypes and predict progression of AD. Participants will visit clinical sites to donate samples multiple times and perform virtual and in-person clinical assessments.

Sponsor: Crownlands

Who Can Participate

Inclusion Criteria

Informed consent provided by the participant or, where applicable, Legally Authorized Representative (LAR) or other substitute decision-maker where permitted by applicable law, as described in Section 8.2.
Male or female, age ≥ 55 years at Screening.
Fluency of subject and study partner in English sufficient to complete all cognitive and self-report assessments without interpreter assistance.
Adequate visual and auditory acuity (with correction permitted) sufficient to complete neuropsychological testing.
Not pregnant or lactating.
Medications stable ≥ 4 weeks before screening.
GDS-15 \< 6 (i.e., 0-5 inclusive; no current significant depression).
Available study partner who has known the participant for ≥ 12 months, maintains \~10+ hours per week of in-person or telephone contact, and is willing to attend study visits and complete informant-rated assessments.
Willing to complete olfactory brushing, smell testing, and venous blood draw.
Willing to commit to baseline and follow-up visits across study duration.
In the opinion of the Investigator, able to comply with the protocol-specified visit schedule and procedures for the full study duration.

Exclusion Criteria

Current or active clinically significant neurological disorder (in the opinion of the Investigator) other than the disorders in the study arms, including but not limited to:
Parkinson's disease, dementia with Lewy bodies, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, Huntington's disease, prion disease, multi-infarct dementia, normal pressure hydrocephalus, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, significant head trauma with persistent deficits, or known structural brain abnormalities.
Active or unstable major psychiatric illness (DSM-5 schizophrenia spectrum, bipolar I, or severe major depressive disorder with active suicidality) within 6 months prior to Screening; history of schizophrenia at any time.
Psychotic features, agitation, or behavioral problems within the last 3 months that could interfere with protocol compliance.
Current substance use disorder (DSM-5 moderate or severe), or alcohol use disorder within 24 months prior to Screening.
Active malignancy under treatment, or malignancy with expected survival \< 30 months (excluding non-melanoma skin cancer and localized prostate cancer on active surveillance).
Participation in studies collecting neuropsychological measures more than once per year.
Presence of previous nasal surgery or other anatomical abnormalities that could interfere with the procedure on both sides of the nose, at the discretion of the clinician administering the Olfactory Brushing.
Active respiratory infection or recent history of respiratory infection within the past two weeks.
Known allergy or adverse reaction to topical anesthetics or decongestants used in the study (e.g., lidocaine, tetracaine, oxymetazoline).
Any other medical or psychiatric condition or lab abnormality that, in the opinion of the Investigator, might preclude participation or render the participant unsuitable for study enrollment. Cognitively Normal (CN) Additional Inclusion Criteria (CN)
No subjective cognitive complaint reported by participant AND no cognitive -complaint reported by study partner.
No current or prior clinical diagnosis of MCI, Alzheimer's disease, or any other dementia, and no current clinical diagnosis of a neurological or neuropsychiatric disease.
MMSE score ≥ 27 / 30 at Screening.
Global Clinical Dementia Rating (CDR) = 0 at Screening.
CDR Sum of Boxes (CDR-SB) = 0 at Screening.
Performance within 1.0 standard deviation of demographically adjusted norms on the Rey Auditory Verbal Learning Test (RAVLT) Delayed Recall. Additional Exclusion Criteria (CN)
Current or prior use of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) or memantine for any indication.
Current or prior use of anti-amyloid monoclonal antibody disease-modifying therapy (aducanumab, lecanemab, donanemab, or any investigational anti-amyloid mAb). Mild Cognitive Impairment (MCI) Additional Inclusion Criteria (MCI)
Subjective cognitive complaint reported by participant OR partner-verified memory complaint reported by study partner.
MMSE score ≥ 24 and ≤ 30 at Screening.
Global CDR = 0.5 at Screening.
CDR-SB ≥ 0.5 and \< 3 at Screening; CDR Memory Box ≥ 0.5.
Performance ≥ 1.5 standard deviations below demographically adjusted norms on the RAVLT Delayed Recall (or equivalent episodic memory criterion per the Petersen / NIA-AA MCI framework).
Preserved general functional ability such that the participant does not meet criteria for dementia (i.e., does not meet AD criteria in Section 7.3). Alzheimer's Disease (AD) Additional Inclusion Criteria (AD)
Confirmed clinical diagnosis of probable Alzheimer's disease by a qualified specialist (cognitive neurologist, geriatric psychiatrist, or equivalent), consistent with NIA-AA 2011 (McKhann et al.) or NIA-AA 2018 Research Framework biological criteria.
MMSE score ≥ 16 and ≤ 26 at Screening.
Global CDR ≥ 1 at Screening.
CDR-SB ≥ 3 at Screening.
CDR Memory Box score ≥ 0.5 at Screening.
Partner-verified history of progressive cognitive decline of ≥ 6 months duration.
Functional impairment consistent with dementia, as documented on the CDR Functional Domains (Community Affairs, Home \& Hobbies, Personal Care); participant able to complete protocol.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Germantown?

Yes, this clinical trial (NCT07611396) has an active research site in Germantown, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Alzheimer s Disease Treatment Options in Germantown, MD

If you're searching for alzheimer s disease treatment options in Germantown, MD, this clinical trial (NCT07611396) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Germantown research site is actively enrolling participants for this clinical trial. You'll receive care from experienced alzheimer s disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all alzheimer s disease clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Germantown, MD

See all alzheimers disease clinical trials recruiting in Germantown — not just this study.

Browse Alzheimers Disease Trials in Germantown →

Browse More Trials by Condition

Alzheimers Disease TrialsAnkylosing Spondylitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Germantown?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Germantown, MD